-
Security Type
-
Equity
-
Min Investment
-
$100
-
Offering Date
-
April 15, 2021
Company Description
Developing new classes of drugs to address incurable autoimmune diseases
Perks
Invest $5,000+ Zoom call with the founders + lab tour
Invest $10,000+ Lunch + lab tour with the founders next time you're in town
Key Deal Facts
$553k raised to date, plus $310k on the same terms
CEO led the 1st clinical trials in the world evaluating exosomes as a treatment for autoimmune disease
Targeting 25M affected by immune-mediated diseases in US, equal to $150B in medical costs/year
Our intellectual property is patent-protected
Raising $2M for pre-clinical product development and IND enabling animal studies
Management Team / Advisory Board Bios
Milad Riazifar, CEO
Exosome biologist with 10+ years of experience in exosome research and clinical development. Led the first clinical trial using exosomes in autoimmune disease to treat Type 1 Diabetes.
Todd Schurr, COO
Multidisciplinary engineer with biomanufacturing experience. His expertise in cGMP manufacturing and process automation are key to streamlining the regulatory approval process.
Cameron Taylor, CTO
Biomedical engineer with extensive experience in stem cell biology and protein engineering. His expertise in gene editing is key to the development of the technology platform.
